Citation

  • Authors: Cicero J. et al.
  • Year: 2023
  • Journal: Exp Hematol Oncol . 12 104
  • Applications: in vitro / DNA / jetOPTIMUS
  • Cell types:
    1. Name: BT-549
      Description: Human breast ductal carcinoma cells
      Known as:
    2. Name: MDA-MB-231
      Description: Human breast adenocarcinoma cells
      Known as: MDAMB231

Method

For Src FRET biosensor experiments, cancer cells were seeded in 100 mm diameter dishes (24 h, 37 °C, CO2 5%). 4 µg of plasmid was diluted in 500 µL of jetOPTIMUS buffer solution and 5 µL of jetOPTIMUS was added for 10 minutes. The mixture was incorporated into the cell medium (6 h, 37 °C, CO2, 5%).

Abstract

Background: Triple-Negative Breast Cancer is particularly aggressive, and its metastasis to the brain has a significant psychological impact on patients' quality of life, in addition to reducing survival. The development of brain metastases is particularly harmful in triple-negative breast cancer (TNBC). To date, the mechanisms that induce brain metastasis in TNBC are poorly understood. Methods: Using a human blood-brain barrier (BBB) in vitro model, an in vitro 3D organotypic extracellular matrix, an ex vivo mouse brain slices co-culture and in an in vivo xenograft experiment, key step of brain metastasis were recapitulated to study TNBC behaviors. Results: In this study, we demonstrated for the first time the involvement of the precursor of Nerve Growth Factor (proNGF) in the development of brain metastasis. More importantly, our results showed that proNGF acts through TrkA independent of its phosphorylation to induce brain metastasis in TNBC. In addition, we found that proNGF induces BBB transmigration through the TrkA/EphA2 signaling complex. More importantly, our results showed that combinatorial inhibition of TrkA and EphA2 decreased TBNC brain metastasis in a preclinical model. Conclusions: These disruptive findings provide new insights into the mechanisms underlying brain metastasis with proNGF as a driver of brain metastasis of TNBC and identify TrkA/EphA2 complex as a potential therapeutic target.

Go to